Top

Published in:

01-05-2018 | Original Research Paper

The peptide lycosin-I attenuates TNF-α-induced inflammation in human umbilical vein endothelial cells via IκB/NF-κB signaling pathway

Authors: Xianyao Li, Yaqin Tang, Binbin Ma, Zheng Wang, Jinying Jiang, Shengjie Hou, Shuhang Wang, Jie Zhang, Meichun Deng, Zhigui Duan, Xing Tang, Alex F. Chen, Liping Jiang

Published in: Inflammation Research | Issue 5/2018

Abstract

Objective

The peptide lycosin-I has anti-bacterial and anti-cancer capacities. However, the anti-inflammatory activity of lycosin-I remains unknown. We investigated whether lycosin-I could attenuate inflammation.

Materials and methods

Human umbilical vein endothelial cells (HUVECs) were treated with lycosin-I before exposure to tumor necrosis factor-α (TNF-α). The expression of intercellular cell adhesion molecule-1 (ICAM-1), nuclear transcription factor-kappa B (NF-κB) p65 and inhibitory subunit of NF-κB alpha (IκBα) was evaluated by western blot. The expression of interleukin-6 (IL-6) and interleukin-8 (IL-8) was detected by quantitative RT-PCR or ELISA. Immunofluorescence analysis was used to determine the impact of lycosin-I on NF-κB pathway. C57BL/6 mice were pretreated with lycosin-I before exposure with lipopolysaccharide (LPS).

Results

Lycosin-I significantly reduced the TNF-α-enhanced expression of IL-6, IL-8 and ICAM-1. Lycosin-I also inhibited the human monocyte cells adhesion to HUVECs. We further demonstrated that lycosin-I could effectively suppress the reaction of endothelial cells to TNF-α by inhibiting IκBα degradation. Subsequently, the phosphorylation and translocation of NF-κB p65 could also be attenuated. Furthermore, lycosin-I exhibited a significant protection of C57BL/6 mice against LPS-induced death.

Conclusions

Our results suggested that the anti-inflammatory activity of lycosin-I was associated with NF-κB activation and lycosin-I had potential to be a novel therapeutic candidate for inflammatory diseases.

Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115 – 26. https://doi.org/10.1056/nejm199901143400207.CrossRefPubMed

Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med. 2012;16(9):1978–90. https://doi.org/10.1111/j.1582-4934.2012.01552.x.CrossRefPubMedPubMedCentral

Libby P. Inflammation in atherosclerosis. arteriosclerosis, thrombosis, and vascular biology. 2012;32(9):2045–51. https://doi.org/10.1161/atvbaha.108.179705.

Yu BL, Wang SH, Peng DQ, Zhao SP. HDL and immunomodulation: an emerging role of HDL against atherosclerosis. Immunol Cell Biol. 2010;88(3):285–90. https://doi.org/10.1038/icb.2009.112.CrossRefPubMed

Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997;80(9A):11I-6I.

Old LJ. Tumor necrosis factor (TNF). Science. 1985;230(4726):630–2.CrossRefPubMed

Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology. 2005;115(1):1–20. https://doi.org/10.1111/j.1365-2567.2005.02143.x.CrossRefPubMedPubMedCentral

Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12(2):147–68. https://doi.org/10.1038/nrd3930.CrossRefPubMedPubMedCentral

Chai H, Wang Q, Huang L, Xie T, Fu Y. Ginsenoside Rb1 inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Biol Pharm Bull. 2008;31(11):2050–6.CrossRefPubMed

10.

Chang CC, Chu CF, Wang CN, Wu HT, Bi KW, Pang JH, et al. The anti-atherosclerotic effect of tanshinone IIA is associated with the inhibition of TNF-alpha-induced VCAM-1, ICAM-1 and CX3CL1 expression. Phytomed: Int J Phytother Phytopharmacol. 2014;21(3):207 – 16. https://doi.org/10.1016/j.phymed.2013.09.012.CrossRef

11.

Sengul S, Zwizinski C, Batuman V. Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells. Am J Physiol Renal Physiol. 2003;284(6):F1245-54. https://doi.org/10.1152/ajprenal.00350.2002.CrossRefPubMed

12.

de Haij S, Bakker AC, van der Geest RN, Haegeman G, Vanden Berghe W, Aarbiou J, et al. NF-kappaB mediated IL-6 production by renal epithelial cells is regulated by c-jun NH2-terminal kinase. J Am Soc Nephrol: JASN. 2005;16(6):1603–11. https://doi.org/10.1681/asn.2004090781.CrossRefPubMed

13.

Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Investig. 1998;101(2):353–63. https://doi.org/10.1172/jci1195.CrossRefPubMedPubMedCentral

14.

Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr, et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999;398(6729):718–23. https://doi.org/10.1038/19546.CrossRefPubMed

15.

Fenyo IM, Gafencu AV. The involvement of the monocytes/macrophages in chronic inflammation associated with atherosclerosis. Immunobiology. 2013;218(11):1376–84. https://doi.org/10.1016/j.imbio.2013.06.005.CrossRefPubMed

16.

Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709–21. https://doi.org/10.1038/nri3520.CrossRefPubMedPubMedCentral

17.

Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Ann Rev Immunol. 1994;12:141–79. https://doi.org/10.1146/annurev.iy.12.040194.001041.CrossRef

18.

Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995;9(10):899–909.CrossRefPubMed

19.

Newton K, Dixit VM. Signaling in innate immunity and inflammation. Cold Spring Harbor Perspect Biol. 2012;4(3). https://doi.org/10.1101/cshperspect.a006049.

20.

Morris-Rosenfeld S, Lipinski MJ, McNamara CA. Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol. 2014;10(1):77–89. https://doi.org/10.1586/1744666x.2014.857602.CrossRefPubMed

21.

Kondkar AA, Abu-Amero KK. Utility of circulating microRNAs as clinical biomarkers for cardiovascular diseases. BioMed Res Int. 2015;2015:821823. https://doi.org/10.1155/2015/821823.CrossRefPubMedPubMedCentral

22.

Lee SW, Kim HC, Lee HS, Suh I. Erratum to: thirty-year trends in mortality from cardiovascular diseases in Korea. Korean Circ J. 2015;45(5):442. https://doi.org/10.4070/kcj.2015.45.5.442.CrossRefPubMedPubMedCentral

23.

Abubakar II, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. https://doi.org/10.1016/s0140-6736(14)61682-2.CrossRef

24.

Skarnes RC, Watson DW. Antimicrobial factors of normal tissues and fluids. Bacteriol Rev. 1957;21(4):273–94.PubMedPubMedCentral

25.

Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochimica et biophysica acta. 1999;1462(1–2):11–28.CrossRefPubMed

26.

Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol. 2005;3(3):238–50. https://doi.org/10.1038/nrmicro1098.CrossRefPubMed

27.

Wang L, Wang YJ, Liu YY, Li H, Guo LX, Liu ZH, et al. In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrobial Agents Chemother. 2014;58(11):6999–7002. https://doi.org/10.1128/AAC.03279-14.CrossRef

28.

Huang L, Tang Y, Qin J, Peng Y, Yuan Q, Zhang F, et al. Vasoactive intestinal peptide enhances TNF-alpha-induced IL-6 and IL-8 synthesis in human proximal renal tubular epithelial cells by NF-kappaB-dependent mechanism. Inflammation. 2012;35(3):1154–60. https://doi.org/10.1007/s10753-011-9423-4.CrossRefPubMed

29.

Zhang Z, Mu L, Tang J, Duan Z, Wang F, Wei L, et al. A small peptide with therapeutic potential for inflammatory acne vulgaris. PLoS One. 2013;8(8):e72923. https://doi.org/10.1371/journal.pone.0072923.CrossRefPubMedPubMedCentral

30.

Fontes JA, Rose NR, Cihakova D. The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine. 2015;74(1):62–8. https://doi.org/10.1016/j.cyto.2014.12.024.CrossRefPubMedPubMedCentral

31.

Feng M, Shu Y, Yang Y, Zheng X, Li R, Wang Y, et al. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses. Neurochem Int. 2014;64:64–72. https://doi.org/10.1016/j.neuint.2013.11.007.CrossRefPubMed

32.

Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circulation research. 2007;101(3):234–47. https://doi.org/10.1161/CIRCRESAHA.107.151860b.CrossRefPubMed

33.

Wang B, Wei H, Prabhu L, Zhao W, Martin M, Hartley AV, et al. Role of novel serine 316 phosphorylation of the p65 subunit of NF-kappaB in differential gene regulation. J Biol Chem. 2015;290(33):20336–47. https://doi.org/10.1074/jbc.M115.639849.CrossRefPubMedPubMedCentral

34.

Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci. 2005;30(1):43–52. https://doi.org/10.1016/j.tibs.2004.11.009.CrossRefPubMed

35.

Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066–71. https://doi.org/10.1056/nejm199704103361506.CrossRefPubMed

36.

Brown JD, Lin CY, Duan Q, Griffin G, Federation AJ, Paranal RM, et al. NF-kappaB directs dynamic super enhancer formation in inflammation and atherogenesis. Mol Cell. 2014;56(2):219–31. https://doi.org/10.1016/j.molcel.2014.08.024.CrossRefPubMedPubMedCentral

37.

Mako V, Czucz J, Weiszhar Z, Herczenik E, Matko J, Prohaszka Z, et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1beta, TNF-alpha, and LPS. Cytometry Part A J Int Soc Anal Cytol. 2010;77(10):962–70. https://doi.org/10.1002/cyto.a.20952.CrossRef

38.

Chistiakov DA, Sobenin IA, Orekhov AN. Regulatory T cells in atherosclerosis and strategies to induce the endogenous atheroprotective immune response. Immunol Lett. 2013;151(1–2):10–22. https://doi.org/10.1016/j.imlet.2013.01.014.CrossRefPubMed

39.

Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med. 2014;127(1):12–8. https://doi.org/10.1016/j.amjmed.2013.08.013.CrossRefPubMed

40.

Khalil RA. Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease. Biochem Pharmacol. 2013;86(12):1627–42. https://doi.org/10.1016/j.bcp.2013.09.024.CrossRefPubMed

41.

Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725–34. https://doi.org/10.1038/nri910.CrossRefPubMed

42.

Fu Y, Wei Z, Zhou E, Zhang N, Yang Z. Cyanidin-3-O-beta-glucoside inhibits lipopolysaccharide-induced inflammatory response in mouse mastitis model. J Lipid Res. 2014;55(6):1111–9. https://doi.org/10.1194/jlr.M047340.CrossRefPubMedPubMedCentral

43.

Ding Y, Liao W, He X, Xiang W, Lu Q. CSTMP exerts anti-inflammatory effects on LPS-induced human renal proximal tubular epithelial cells by inhibiting TLR4-mediated NF-kappaB pathways. Inflammation. 2016;39(2):849–59. https://doi.org/10.1007/s10753-016-0315-5.CrossRefPubMed

44.

Ledebur HC, Parks TP. Transcriptional regulation of the intercellular adhesion molecule-1 gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem. 1995;270(2):933–43.CrossRefPubMed

45.

Lockyer JM, Colladay JS, Alperin-Lea WL, Hammond T, Buda AJ. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circul Res. 1998;82(3):314–20.CrossRef

46.

Wang L, Xu Y, Yu Q, Sun Q, Gu Q, Xu X. H-RN, a novel antiangiogenic peptide derived from hepatocyte growth factor inhibits inflammation in vitro and in vivo through PI3K/AKT/IKK/NF-kappaB signal pathway. Biochem Pharmacol. 2014;89(2):255–65. https://doi.org/10.1016/j.bcp.2014.02.026.CrossRefPubMed

47.

Wan M, Liu J, Ouyang X. Nucleotide-binding oligomerization domain 1 regulates Porphyromonas gingivalis-induced vascular cell adhesion molecule 1 and intercellular adhesion molecule 1 expression in endothelial cells through NF-kappaB pathway. J Periodontal Res. 2015;50(2):189–96. https://doi.org/10.1111/jre.12192.CrossRefPubMed

48.

Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Investig. 2001;107(3):255–64. https://doi.org/10.1172/jci10373.CrossRefPubMedPubMedCentral

49.

Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 2010;86(2):211–8. https://doi.org/10.1093/cvr/cvq076.CrossRefPubMedPubMedCentral

50.

Kurokouchi K, Kambe F, Kikumori T, Sakai T, Sarkar D, Ishiguro N, et al. Effects of glucocorticoids on tumor necrosis factor alpha-dependent activation of nuclear factor kappaB and expression of the intercellular adhesion molecule 1 gene in osteoblast-like ROS17/2.8 cells. J Bone Miner Res. 2000;15(9):1707–15. https://doi.org/10.1359/jbmr.2000.15.9.1707.CrossRefPubMed

51.

Eberhardt W, Schulze M, Engels C, Klasmeier E, Pfeilschifter J. Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors. Mol Endocrinol (Baltimore. Md). 2002;16(8):1752–66. https://doi.org/10.1210/me.2001-0278.CrossRef

52.

Vital AL, Goncalo M, Cruz MT, Figueiredo A, Duarte CB, Lopes MC. Dexamethasone prevents granulocyte-macrophage colony-stimulating factor-induced nuclear factor-kappaB activation, inducible nitric oxide synthase expression and nitric oxide production in a skin dendritic cell line. Mediators Inflammation. 2003;12(2):71–8. https://doi.org/10.1080/0962935031000097673.CrossRef

53.

Ma W, Gee K, Lim W, Chambers K, Angel JB, Kozlowski M, et al. Dexamethasone inhibits IL-12p40 production in lipopolysaccharide-stimulated human monocytic cells by down-regulating the activity of c-Jun N-terminal kinase, the activation protein-1, and NF-kappa B transcription factors. J Immunol (Baltimore: 1950). 2004;172(1):318–30.

54.

Mattioli I, Sebald A, Bucher C, Charles RP, Nakano H, Doi T, et al. Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappa B kinase beta and controls the kinetics of p65 nuclear import. J Immunol (Baltimore: 1950). 2004;172(10):6336–44.

55.

Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015;372(14):1301–11. https://doi.org/10.1056/NEJMoa1500896.CrossRefPubMed

56.

Luan YY, Dong N, Xie M, Xiao XZ, Yao YM. The significance and regulatory mechanisms of innate immune cells in the development of sepsis. J Interferon Cytokine Res. 2014;34(1):2–15. https://doi.org/10.1089/jir.2013.0042.CrossRefPubMedPubMedCentral

57.

Luan YY, Yao YM, Xiao XZ, Sheng ZY. Insights into the apoptotic death of immune cells in sepsis. J Interferon Cytokine Res. 2015;35(1):17–22. https://doi.org/10.1089/jir.2014.0069.CrossRefPubMedPubMedCentral

Title: The peptide lycosin-I attenuates TNF-α-induced inflammation in human umbilical vein endothelial cells via IκB/NF-κB signaling pathway
Authors: Xianyao Li
Yaqin Tang
Binbin Ma
Zheng Wang
Jinying Jiang
Shengjie Hou
Shuhang Wang
Jie Zhang
Meichun Deng
Zhigui Duan
Xing Tang
Alex F. Chen
Liping Jiang
Publication date: 01-05-2018
Publisher: Springer International Publishing
Published in: Inflammation Research / Issue 5/2018
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-018-1138-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The peptide lycosin-I attenuates TNF-α-induced inflammation in human umbilical vein endothelial cells via IκB/NF-κB signaling pathway

Abstract

Objective

Materials and methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2018

Vascular endothelium dysfunction: a conservative target in metabolic disorders

Cathepsin H deficiency in mice induces excess Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade

Heme oxygenase-1/biliverdin/carbon monoxide pathway downregulates hypernociception in rats by a mechanism dependent on cGMP/ATP-sensitive K+ channels

Luteolin activates ERK1/2- and Ca2+-dependent HO-1 induction that reduces LPS-induced HMGB1, iNOS/NO, and COX-2 expression in RAW264.7 cells and mitigates acute lung injury of endotoxin mice

The host control of a clinical isolate strain of P. aeruginosa infection is independent of Nod-1 but depends on MyD88

Evolving notions on immune response in colorectal cancer and their implications for biomarker development

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page